ABCL

SEC source: 0000899243-21-022899 · doc4.xml · derivative · entry 5

Stimart Tryn · CIK 0001834424 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Shares · 250,000 shares

Expires 2030-10-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Previously reported on Form 3 filed on December 11, 2020 and Form 4 filed on December 17, 2020. The vesting schedule was amended such that all of the shares subject to such option were vested as of March 24, 2021.

SEC source: 0000899243-21-022899 · doc4.xml · derivative · entry 4

Stimart Tryn · CIK 0001834424 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,250,000

Underlying: Common Shares · 750,000 shares

Expires 2029-08-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Previously reported on Form 3 filed on December 11, 2020. The vesting schedule was amended as follow: 25% of the shares subject to such option vest and become exercisable on August 22, 2020; 6.25% of the shares subject to such option vest and become exercisable on November 22, 2020 and February 22, 2021; 4.70% of the shares subject to such option vest and become exercisable on on July 1, 2022; 8.9% of the shares subject to such option vest and become exercisable on October 1, 2022; 7.4% of the shares subject to such option vest and become exercisable on January 1, 2023; 10.40% of the shares subject to such option vest and become exercisable on April 1, 2023; 8.90% of the shares subject to such option vest and become exercisable on July 1, 2023 and October 1, 2023; 2.70% of the shares subject to such option vest and become exercisable on January 1, 2024;

F2 · derivative.exercise_date: (Continued from footnote 1) and 2.65% of the shares subject to such option vest and become exercisable on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025.

SEC source: 0000899243-21-022899 · doc4.xml · nonDerivative · entry 2

Stimart Tryn · CIK 0001834424 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-022899 · doc4.xml · nonDerivative · entry 1

Stimart Tryn · CIK 0001834424 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 750,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-022894 · doc4.xml · derivative · entry 5

Booth Andrew · CIK 0001834411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,950,000

Underlying: Common Shares · 600,000 shares

Expires 2029-08-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 2,000,000 shares subject to the option vested and became exercisable on March 23, 2020. The remaining 3,550,000 shares (the "Remaining Shares") subject to the option vest and become exercisable as follows: 25% of the Remaining Shares subject to such option vested and became exercisable on August 22, 2020 and the remainder of the Remaining Shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0000899243-21-022894 · doc4.xml · derivative · entry 4

Booth Andrew · CIK 0001834411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Shares · 600,000 shares

Expires 2026-06-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0000899243-21-022894 · doc4.xml · nonDerivative · entry 2

Booth Andrew · CIK 0001834411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,200,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-022894 · doc4.xml · nonDerivative · entry 1

Booth Andrew · CIK 0001834411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-006967 · doc5.xml · nonDerivative · entry 1

Thermopylae Holdings Ltd. · CIK 0001834449 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,557,290

F1 · shares: This transaction represents a charitable donation of 1,250,000 common shares the reporting person donated on May 24, 2021.

SEC source: 0001209191-22-006963 · doc5.xml · nonDerivative · entry 2

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 54,557,290

F4 · shares: This transaction represents a charitable donation of 1,250,000 common shares donated by Thermopylae Holdings Ltd. on May 24, 2021.

F5 · ownership.nature: These shares are held by Thermopylae Holdings Ltd., which is an entity wholly owned by the reporting person.

SEC source: 0001209191-22-006963 · doc5.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · shares: This transaction represents a charitable donation of 223,500 common shares donated by Hankla Family Trust (2019) on May 24, 2021.

F2 · balance_after: Due to clerical error, the number of shares held by Hankla Family Trust (2019) was overstated by 10,000 shares on the reporting person's prior Form 4 filings.

F3 · ownership.nature: These shares are held by Hankla Family Trust (2019), of which the reporting person and his spouse are joint trustees. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.

SEC source: 0000899243-21-016935 · doc4.xml · derivative · entry 2

Falconer Ester · CIK 0001844479 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 1,000,000 shares

Expires 2025-08-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price reported above was converted from the Canadian exercise price of CAD $0.0450 using an exchange rate on August 4, 2015 of CAD $1.313 = US $1.00.

F2 · derivative.exercise_date: As of the date of the transaction, the option was fully vested and exercisable.

SEC source: 0000899243-21-016935 · doc4.xml · nonDerivative · entry 1

Falconer Ester · CIK 0001844479 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-20-034340 · doc4.xml · derivative · entry 7

Hayden Michael R · CIK 0001352908 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 117,647 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the Issuer's initial public offering into Common Shares at a conversion price equal to $17.00 per Common Share.

F7 · derivative.expiration_date: The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the Issuer's initial public offering into Common Shares at a conversion price equal to $17.00 per Common Share.

F1 · ownership.nature: These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.

SEC source: 0000899243-20-034340 · doc4.xml · nonDerivative · entry 3

Hayden Michael R · CIK 0001352908 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 118,245

SEC source: 0000899243-20-034340 · doc4.xml · nonDerivative · entry 2

Hayden Michael R · CIK 0001352908 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,103,397

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the Issuer's initial public offering into Common Shares at a conversion price equal to $17.00 per Common Share.

F1 · ownership.nature: These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.

SEC source: 0000899243-20-034349 · doc4.xml · derivative · entry 6

HAMER JOHN · CIK 0001198174 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 29,411 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share.

F3 · derivative.expiration_date: The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share.

F1 · ownership.nature: These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP. JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person is one of the managing members of JNK. The managing members of JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that he is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any, by virtue of his interest in DCVC Bio GP and JNK, as applicable.

SEC source: 0000899243-20-034349 · doc4.xml · derivative · entry 5

HAMER JOHN · CIK 0001198174 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 8,023,710 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F2 · derivative.exercise_date: The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F2 · derivative.expiration_date: The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F1 · ownership.nature: These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP. JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person is one of the managing members of JNK. The managing members of JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that he is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any, by virtue of his interest in DCVC Bio GP and JNK, as applicable.

SEC source: 0000899243-20-034349 · doc4.xml · derivative · entry 4

HAMER JOHN · CIK 0001198174 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 21,052,640 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F2 · derivative.exercise_date: The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F2 · derivative.expiration_date: The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F1 · ownership.nature: These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP. JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person is one of the managing members of JNK. The managing members of JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that he is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any, by virtue of his interest in DCVC Bio GP and JNK, as applicable.

SEC source: 0000899243-20-034349 · doc4.xml · nonDerivative · entry 2

HAMER JOHN · CIK 0001198174 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 29,105,761

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share.

F1 · ownership.nature: These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP. JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person is one of the managing members of JNK. The managing members of JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that he is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any, by virtue of his interest in DCVC Bio GP and JNK, as applicable.

SEC source: 0000899243-20-034349 · doc4.xml · nonDerivative · entry 1

HAMER JOHN · CIK 0001198174 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 29,076,350

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F1 · ownership.nature: These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP. JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person is one of the managing members of JNK. The managing members of JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that he is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any, by virtue of his interest in DCVC Bio GP and JNK, as applicable.

SEC source: 0001209191-20-064259 · doc4.xml · derivative · entry 5

DCVC Bio, L.P. · CIK 0001735069 · 10% owner

Bogue Zachary · CIK 0001836157 · 10% owner

DCVC Bio GP, LLC · CIK 0001735070 · 10% owner

JNK Capital Management, LLC · CIK 0001836273 · 10% owner

Ocko Matthew · CIK 0001836089 · 10% owner

Stead Kiersten · CIK 0001836117 · 10% owner

ZNM Capital Management, LLC · CIK 0001836103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 29,411 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share.

F4 · derivative.expiration_date: The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share.

F2 · ownership.nature: These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio.

F3 · ownership.nature: (Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any.

SEC source: 0001209191-20-064259 · doc4.xml · derivative · entry 4

DCVC Bio, L.P. · CIK 0001735069 · 10% owner

Bogue Zachary · CIK 0001836157 · 10% owner

DCVC Bio GP, LLC · CIK 0001735070 · 10% owner

JNK Capital Management, LLC · CIK 0001836273 · 10% owner

Ocko Matthew · CIK 0001836089 · 10% owner

Stead Kiersten · CIK 0001836117 · 10% owner

ZNM Capital Management, LLC · CIK 0001836103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 8,023,710 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F1 · derivative.exercise_date: The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F1 · derivative.expiration_date: The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F2 · ownership.nature: These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio.

F3 · ownership.nature: (Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any.

SEC source: 0001209191-20-064259 · doc4.xml · derivative · entry 3

DCVC Bio, L.P. · CIK 0001735069 · 10% owner

Bogue Zachary · CIK 0001836157 · 10% owner

DCVC Bio GP, LLC · CIK 0001735070 · 10% owner

JNK Capital Management, LLC · CIK 0001836273 · 10% owner

Ocko Matthew · CIK 0001836089 · 10% owner

Stead Kiersten · CIK 0001836117 · 10% owner

ZNM Capital Management, LLC · CIK 0001836103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 21,052,640 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F1 · derivative.exercise_date: The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F1 · derivative.expiration_date: The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F2 · ownership.nature: These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio.

F3 · ownership.nature: (Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any.

SEC source: 0001209191-20-064259 · doc4.xml · nonDerivative · entry 2

DCVC Bio, L.P. · CIK 0001735069 · 10% owner

Bogue Zachary · CIK 0001836157 · 10% owner

DCVC Bio GP, LLC · CIK 0001735070 · 10% owner

JNK Capital Management, LLC · CIK 0001836273 · 10% owner

Ocko Matthew · CIK 0001836089 · 10% owner

Stead Kiersten · CIK 0001836117 · 10% owner

ZNM Capital Management, LLC · CIK 0001836103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 29,105,761

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share.

F2 · ownership.nature: These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio.

F3 · ownership.nature: (Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any.

SEC source: 0001209191-20-064259 · doc4.xml · nonDerivative · entry 1

DCVC Bio, L.P. · CIK 0001735069 · 10% owner

Bogue Zachary · CIK 0001836157 · 10% owner

DCVC Bio GP, LLC · CIK 0001735070 · 10% owner

JNK Capital Management, LLC · CIK 0001836273 · 10% owner

Ocko Matthew · CIK 0001836089 · 10% owner

Stead Kiersten · CIK 0001836117 · 10% owner

ZNM Capital Management, LLC · CIK 0001836103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 29,076,350

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F2 · ownership.nature: These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio.

F3 · ownership.nature: (Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any.

SEC source: 0000899243-20-034341 · doc4.xml · nonDerivative · entry 2

Montalbano John S. · CIK 0001834423 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 5,000

SEC source: 0000899243-20-034341 · doc4.xml · nonDerivative · entry 1

Montalbano John S. · CIK 0001834423 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

SEC source: 0000899243-20-034342 · doc4.xml · nonDerivative · entry 2

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 61,580

SEC source: 0000899243-20-034342 · doc4.xml · nonDerivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,006,000

SEC source: 0000899243-20-034339 · doc4.xml · nonDerivative · entry 2

Stimart Tryn · CIK 0001834424 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 250

SEC source: 0000899243-20-034339 · doc4.xml · nonDerivative · entry 1

Stimart Tryn · CIK 0001834424 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250

SEC source: 0000899243-20-034355 · doc4.xml · derivative · entry 18

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 24,660 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_price: The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal $17.00 per Common Share plus 6,840 Common Shares.

F9 · derivative.exercise_date: The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal $17.00 per Common Share plus 6,840 Common Shares.

F9 · derivative.expiration_date: The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal $17.00 per Common Share plus 6,840 Common Shares.

F10 · ownership.nature: These shares are held of record by The Founders Fund Growth Principals Fund, LP ("FFGP"). The Reporting Person is one of the managing members of FFGM, which is the general partner of FFGP. The Reporting Person may be deemed to have beneficial ownership over the securities held by FFGP. The Reporting Person disclaims beneficial ownership over the shares held by FFGP except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-034355 · doc4.xml · derivative · entry 17

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 382,357 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share plus 106,060 Common Shares.

F7 · derivative.exercise_date: The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share plus 106,060 Common Shares.

F7 · derivative.expiration_date: The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share plus 106,060 Common Shares.

F8 · ownership.nature: These shares are held of record by The Founders Fund Growth, LP ("FFG"). The Reporting Person is one of the managing members of The Founders Fund Growth Management, LLC ("FFGM"), which is the general partner of FFG. The Reporting Person may be deemed to have beneficial ownership over the securities held by FFG. The Reporting Person disclaims beneficial ownership over the shares held by FFG except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-034355 · doc4.xml · derivative · entry 16

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 2,477,100 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share plus 687,100 Common Shares.

F6 · derivative.exercise_date: The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share plus 687,100 Common Shares.

F6 · derivative.expiration_date: The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share plus 687,100 Common Shares.

F1 · ownership.nature: These shares are held of record by ABE Investments LLC. The Reporting Person is the beneficial owner of ABE Investments LLC and has sole voting and investment power over the securities held by ABE Investments LLC.

SEC source: 0000899243-20-034355 · doc4.xml · derivative · entry 15

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 29,240 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F2 · derivative.exercise_date: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F2 · derivative.expiration_date: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F5 · ownership.nature: These shares are held of record by The Founders Fund VII Entrepreneurs Fund, LP ("FF-VIIE"). The Reporting Person is one of the managing members of FFVIIM, which is the general partner of FF-VIIE. The Reporting Person may be deemed to have beneficial ownership over the securities held by FF-VIIE. The Reporting Person disclaims beneficial ownership over the shares held by FF-VIIE except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-034355 · doc4.xml · derivative · entry 14

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 401,050 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F2 · derivative.exercise_date: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F2 · derivative.expiration_date: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F4 · ownership.nature: These shares are held of record by The Founders Fund VII Principals Fund, LP ("FF-VIIP"). The Reporting Person is one of the managing members of FFVIIM, which is the general partner of FF-VIIP. The Reporting Person may be deemed to have beneficial ownership over the securities held by FF-VIIP. The Reporting Person disclaims beneficial ownership over the shares held by FF-VIIP except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-034355 · doc4.xml · derivative · entry 13

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 3,343,240 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F2 · derivative.exercise_date: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F2 · derivative.expiration_date: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F3 · ownership.nature: These shares are held of record by The Founders Fund VII, LP ("FF-VII"). The Reporting Person is one of the managing members of The Founders Fund VII Management, LLC ("FFVIIM"), which is the general partner of FF-VII. The Reporting Person may be deemed to have beneficial ownership over the securities held by FF-VII. The Reporting Person disclaims beneficial ownership over the shares held by FF-VII except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-034355 · doc4.xml · derivative · entry 12

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Shares · 3,811,260 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F2 · derivative.exercise_date: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F2 · derivative.expiration_date: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F1 · ownership.nature: These shares are held of record by ABE Investments LLC. The Reporting Person is the beneficial owner of ABE Investments LLC and has sole voting and investment power over the securities held by ABE Investments LLC.

SEC source: 0000899243-20-034355 · doc4.xml · nonDerivative · entry 8

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 24,660

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · price: The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal $17.00 per Common Share plus 6,840 Common Shares.

F10 · ownership.nature: These shares are held of record by The Founders Fund Growth Principals Fund, LP ("FFGP"). The Reporting Person is one of the managing members of FFGM, which is the general partner of FFGP. The Reporting Person may be deemed to have beneficial ownership over the securities held by FFGP. The Reporting Person disclaims beneficial ownership over the shares held by FFGP except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-034355 · doc4.xml · nonDerivative · entry 7

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 382,357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share plus 106,060 Common Shares.

F8 · ownership.nature: These shares are held of record by The Founders Fund Growth, LP ("FFG"). The Reporting Person is one of the managing members of The Founders Fund Growth Management, LLC ("FFGM"), which is the general partner of FFG. The Reporting Person may be deemed to have beneficial ownership over the securities held by FFG. The Reporting Person disclaims beneficial ownership over the shares held by FFG except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-034355 · doc4.xml · nonDerivative · entry 6

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 29,240

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F5 · ownership.nature: These shares are held of record by The Founders Fund VII Entrepreneurs Fund, LP ("FF-VIIE"). The Reporting Person is one of the managing members of FFVIIM, which is the general partner of FF-VIIE. The Reporting Person may be deemed to have beneficial ownership over the securities held by FF-VIIE. The Reporting Person disclaims beneficial ownership over the shares held by FF-VIIE except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-034355 · doc4.xml · nonDerivative · entry 5

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 401,050

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F4 · ownership.nature: These shares are held of record by The Founders Fund VII Principals Fund, LP ("FF-VIIP"). The Reporting Person is one of the managing members of FFVIIM, which is the general partner of FF-VIIP. The Reporting Person may be deemed to have beneficial ownership over the securities held by FF-VIIP. The Reporting Person disclaims beneficial ownership over the shares held by FF-VIIP except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-034355 · doc4.xml · nonDerivative · entry 4

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,343,240

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F3 · ownership.nature: These shares are held of record by The Founders Fund VII, LP ("FF-VII"). The Reporting Person is one of the managing members of The Founders Fund VII Management, LLC ("FFVIIM"), which is the general partner of FF-VII. The Reporting Person may be deemed to have beneficial ownership over the securities held by FF-VII. The Reporting Person disclaims beneficial ownership over the shares held by FF-VII except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-034355 · doc4.xml · nonDerivative · entry 3

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 10,179,880

F1 · ownership.nature: These shares are held of record by ABE Investments LLC. The Reporting Person is the beneficial owner of ABE Investments LLC and has sole voting and investment power over the securities held by ABE Investments LLC.

SEC source: 0000899243-20-034355 · doc4.xml · nonDerivative · entry 2

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 7,179,880

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share plus 687,100 Common Shares.

F1 · ownership.nature: These shares are held of record by ABE Investments LLC. The Reporting Person is the beneficial owner of ABE Investments LLC and has sole voting and investment power over the securities held by ABE Investments LLC.

SEC source: 0000899243-20-034355 · doc4.xml · nonDerivative · entry 1

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,702,780

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.

F1 · ownership.nature: These shares are held of record by ABE Investments LLC. The Reporting Person is the beneficial owner of ABE Investments LLC and has sole voting and investment power over the securities held by ABE Investments LLC.

SEC source: 0000899243-20-034340 · doc4.xml · derivative · entry 6

Hayden Michael R · CIK 0001352908 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: Not disclosed

Underlying: Common Shares · 117,647 shares

Expires not disclosed

F7 · derivative.exercise_price: The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the Issuer's initial public offering into Common Shares at a conversion price equal to $17.00 per Common Share.

F8 · kind: This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F7 · derivative.exercise_date: The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the Issuer's initial public offering into Common Shares at a conversion price equal to $17.00 per Common Share.

F7 · derivative.expiration_date: The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the Issuer's initial public offering into Common Shares at a conversion price equal to $17.00 per Common Share.

F1 · ownership.nature: These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.

SEC source: 0000899243-20-034349 · doc4.xml · derivative · entry 3

HAMER JOHN · CIK 0001198174 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: Not disclosed

Underlying: Common Shares · 29,411 shares

Expires not disclosed

F3 · derivative.exercise_price: The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share.

F4 · kind: This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F3 · derivative.exercise_date: The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share.

F3 · derivative.expiration_date: The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share.

F1 · ownership.nature: These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP. JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person is one of the managing members of JNK. The managing members of JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that he is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any, by virtue of his interest in DCVC Bio GP and JNK, as applicable.

SEC source: 0000899243-20-034355 · doc4.xml · derivative · entry 11

THIEL PETER · CIK 0001211060 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: Not disclosed

Underlying: Common Shares · 24,660 shares

Expires not disclosed

F9 · derivative.exercise_price: The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal $17.00 per Common Share plus 6,840 Common Shares.

F11 · kind: This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F9 · derivative.exercise_date: The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal $17.00 per Common Share plus 6,840 Common Shares.

F9 · derivative.expiration_date: The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal $17.00 per Common Share plus 6,840 Common Shares.

F10 · ownership.nature: These shares are held of record by The Founders Fund Growth Principals Fund, LP ("FFGP"). The Reporting Person is one of the managing members of FFGM, which is the general partner of FFGP. The Reporting Person may be deemed to have beneficial ownership over the securities held by FFGP. The Reporting Person disclaims beneficial ownership over the shares held by FFGP except to the extent of his pecuniary interest therein.